OpenAI Invests in Startup That Uses Brain Implants to Detect Cancer

OpenAI's venture arm and Founders Fund are investing in Coherence Neuro as part of a $45 million seed round. The San Francisco startup is building an implant that uses AI models to decode electrical signals tied to brain tumors and, eventually, to deliver mild stimulation intended to halt their growth. It plans to use the money for a long-term implant trial in patients with glioblastoma, one of the most aggressive brain cancers.

This matters on two tracks. Medically, a device that could track whether a tumor is growing, shrinking or returning, and respond in real time, would be a meaningful advance for a disease with few good options. Strategically, it is another sign that AI companies see neural data as a valuable new resource.

We want to give this one its due. Coherence is not selling mind-reading for productivity. It is aiming at glioblastoma, and its early human work so far is cautious: this summer it briefly tested the implant's recording ability in three people already undergoing tumor surgery at the Royal Melbourne Hospital, with the device in place for roughly 30 minutes as a safety check. Next it is testing recording and stimulation in seven more patients. That is how this kind of research should move, step by step, with patients who stand to benefit.

The company says it can already detect tumor-linked signals in animals. That claim is still animal-stage, and the gap between animal results and human outcomes in brain cancer is notoriously wide. We will believe in the therapy when trial data shows patients living longer or better, not before.

The part that gives us pause is the framing around data. Coherence's CEO describes brain signals as a novel data source that AI companies see value in, and talks about capturing data to train better models. That is honest, and it is also exactly why people should pay attention. Neural recordings are about as personal as data gets.

To its credit, Coherence says plainly that OpenAI will have no access to its brain or health data under the deal. That is the right line, and it contrasts with OpenAI's earlier investment in Merge Labs, the brain-interface company co-founded by its own CEO, where OpenAI said it would collaborate on scientific foundation models. Two investments, two very different data arrangements, and the public is mostly relying on company statements to know which is which.

Where this leads if it scales: a growing number of implanted devices producing continuous neural data, held by startups funded by the same firms building the largest AI models. The medicine could be wonderful. The governance of that data has to be settled before it is valuable, not after.

WIRED notes that OpenAI said in January it was investing in Merge Labs, which emerged with $252 million to pursue ultrasound-based brain decoding. Founders Fund has previously backed Neuralink and CTRL-labs, which Facebook acquired in 2019. Most brain-computer interface work has focused on restoring function for paralyzed people; Coherence is targeting cancer instead.